RHT Consulting and Hult International Business School Students Conduct Leaders and Laggards Analysis
Online, July 6, 2011 (Newswire.com) - RHT Consulting, a leading provider of strategy consulting services in the Life Sciences industry, has conducted a leaders and laggards analysis on top-ranked pharmaceutical companies. RHT Consulting and Hult International Business School students analyzed leading pharmaceutical companies based on business model innovation, operational model innovation and product/service innovation.
The team conducted its leaders and laggards assessment on pharmaceutical companies extracted from Forbes' top 1500 list of companies. The project involved developing metrics based on several financial measures, such as R&D spend growth, operating income results, sales, gross margin, etc. By applying these metrics in the three innovation categories outlined above, the team created a ranking of "best-in-class" leaders and "worst-in-class" laggards. Upon analyzing the leaders and laggards from a benchmarking standpoint, the team then sought to identify which factors caused the leaders to perform better as well as which measures companies should avoid.
The results of the analysis clearly identified the leaders to be strong in both product/service innovation and operational innovation. The team also synthesized key characteristics that leaders have, such as the ability to collaborate. Results, however, did not indicate a clear trend as it relates to business model innovation.
The team was led by Rosemarie Truman of RHT Consulting and was comprised of four international students from Hult: Bijeet Kumar, Farah Mahboob, Raman Ahuja and Varun Kurup.
Bijeet Kumar, project team lead and Hult Master candidate, summarized the team's findings and experience: "We found that a few top players that appear strong based on individual criteria, such as revenue and assets, were proven to be average performers based on a more holistic assessment of innovation criteria. Another key outcome was realizing the area in which innovation was strongest, which was operational model innovation. My team enjoyed working on this project, as the idea of evaluating pharmaceutical companies on the basis of innovation was very appealing."
"Innovation is critical for companies to experience long-term, sustainable growth in any industry," said Rosemarie Truman, Founder and CEO of RHT Consulting. "Our team did phenomenal work in analyzing how innovation has impacted the profitable growth of pharmaceutical companies. Part of our findings revealed that companies who consistently invested in R&D and innovation ranked as leaders and blazed new trails in the industry. We believe our analysis will provide new insights for pharmaceutical companies who want to have sustainable growth."
Results from the leaders and laggards analysis project will be published in a whitepaper at a later date in 2011.
About Hult International Business School
Hult International Business School (formerly known as the Arthur D. Little School of Management) is the first global business school with campuses in Boston, San Francisco, London, Dubai, and Shanghai. The School offers a range of business-focused programs including MBA, Master and Undergraduate degrees. Hult's one-year MBA program is ranked in the top 30 in the world by The Economist and among the top 100 by the Financial Times. www.hult.edu